Vectus Biosystems

Vectus Biosystems Goodwill

Goodwill of Vectus Biosystems (VBS.AX) as of Oct 19, 2026.

Goodwill

-AUD

Last updated:

Goodwill of Vectus Biosystems is 2026 - AUD. Goodwill of Vectus Biosystems was 2025 - AUD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd, based in Rosebery, Australia, operates in the Health Care sector within Biotechnology. The company focuses on drug discovery and development, particularly for fibrosis and hypertension treatments, including conditions affecting the heart, kidneys, and liver. Its lead compound, VB0004, targets tissue hardening and high blood pressure. Vectus also develops Accugen, a platform for accurate DNA and RNA quantification in laboratory testing through its subsidiary Accugen Pty Limited. Vectus Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectus Biosystems stock

On Eulerpool you can find the complete historical development of Goodwill Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Vectus Biosystems historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Vectus Biosystems

All Key Metrics — Vectus Biosystems